CG
EBS icon

Caprock Group’s Emergent Biosolutions EBS Stock Holding History

Caprock Group’s Portfolio EBS Stock Details EBS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-2,700
Closed -$214K – 426
2020
Q2 		$214K Buy
+2,700
New +$201K 0.03% 354
2019
Q2 		– Sell
-4,521
Closed -$228K – 368
2019
Q1 		$228K Sell
4,521
-228
-5% -$13.4K 0.04% 311
2018
Q4 		$282K Sell
4,749
-280
-6% -$18.1K 0.06% 251
2018
Q3 		$331K Sell
5,029
-154
-3% -$8.99K 0.07% 251
2018
Q2 		$262K Sell
5,183
-375
-7% -$19.5K 0.06% 323
2018
Q1 		$293K Buy
+5,558
New +$277K 0.06% 284

Other funds holding EBS

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Neuberger Berman Group
Neuberger Berman Group New York $131B AUM 28.36% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
EARNEST Partners
EARNEST Partners Atlanta, Georgia $24.3B AUM 34.41% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Manulife (Manufacturers Life Insurance)
Manulife (Manufacturers Life Insurance) Canada, Ontario, Canada $116B AUM 26.37% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
SCM
Snyder Capital Management San Francisco, California $5.16B AUM 26.72% 1-Year Est. Return

Caprock Group's EBS Position: Q3 2020 in Review

Caprock Group sold out of Emergent Biosolutions (EBS) in Q3 2020, closing a stake of 2,700 shares — an estimated $214K sold.

Caprock Group first reported a position in EBS in Q1 2018 and held it in 6 quarters. The position peaked at $331K in Q3 2018. 358 funds tracked by Wall St. Rank hold EBS as of Q3 2020.

  • Caprock Group reported no remaining Emergent Biosolutions position as of Q3 2020 after selling out during the quarter.
  • Caprock Group sold 2,700 Emergent Biosolutions shares in Q3 2020, an estimated $214K.
  • Caprock Group first reported a position in Emergent Biosolutions in Q1 2018 and held it in 6 quarters.
  • Caprock Group's Emergent Biosolutions position peaked at $331K in Q3 2018.
  • 358 funds tracked by Wall St. Rank held Emergent Biosolutions as of Q3 2020.

Based on Caprock Group's 13F filing for Q3 2020, filed 29 Oct 2020.